Historical cah News Stories

Cardinal Health Order Express Fuels Specialty Push

Cardinal Health (CAH) bolstered its specialty and logistics positioning this week with the rollout of the Order Express high-speed logistics platform and the finalized acquisition of Specialty Networks. These concrete moves — plus renewed competitive dynamics after OptumRx contract shifts — point to revenue diversification, margin pressure alleviation, and measurable operational improvements investors should track.

Cardinal Health Climbs Near 52-Week High CAH Rally

Cardinal Health (CAH) gained 2.17% on Feb 17, 2026, closing at $225.58 and trading just below its 52-week high of $230.81. The move outpaced healthcare peers amid a modest S&P 500 uptick; trading volume was slightly below the 50-day average. No other major sector-specific headlines emerged in the past week, leaving technical momentum and upcoming catalysts as primary drivers for investors.

Cardinal Health Ups FY26 EPS Outlook to $10+

Cardinal Health raised its FY2026 non‑GAAP EPS guidance to at least $10, citing strong Specialty and BioPharma growth, broad ContinuCare rollout, and successful contract transitions ahead of Medicare drug‑pricing changes—key developments that materially affect CAH shares.

Cardinal Health Surges: Q2 Beat, Guidance Raised!!

Cardinal Health (CAH) reported a strong Q2 FY2026 with a revenue beat, raised full-year EPS guidance, and signaled continued growth from higher-margin specialty services (Sonexus, BioPharma). Technical strength (RS Rating 91) and aggressive capital returns contrast with elevated debt and $4.3B opioid liabilities.